Response to 'Comment on: "Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases"'
- PMID: 32461567
- PMCID: PMC8027024
- DOI: 10.1038/s41433-020-0983-0
Response to 'Comment on: "Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases"'
Conflict of interest statement
The authors declare that they have no conflict of interest.
Comment on
-
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases.Eye (Lond). 2020 Aug;34(8):1341-1356. doi: 10.1038/s41433-020-0770-y. Epub 2020 Jan 30. Eye (Lond). 2020. PMID: 32001821 Free PMC article. Review.
-
Comment on "Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases".Eye (Lond). 2021 Mar;35(3):1024-1025. doi: 10.1038/s41433-020-0982-1. Epub 2020 May 28. Eye (Lond). 2021. PMID: 32467630 Free PMC article. No abstract available.
References
-
- Medicine UNLo. History of Changes for Study: NCT03677934. A phase III study to evaluate the Port Delivery System with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration (Archway). Medicine UNLo; 2020. https://clinicaltrials.gov/ct2/history/NCT03677934. Accessed Apr 27 2020.
-
- Medicine UNLo. History of Changes for Study: NCT03683251. Extension study for the Port Delivery System with ranibizumab (Portal). Medicine UNLo; 2020. https://clinicaltrials.gov/ct2/history/NCT03683251?V_10=View. Accessed Apr 27 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical